Endpoints at #JPM25 - January 13-14, 2025 - San Francisco
In the biopharma world, the new year doesn’t start on January 1 — it starts when the industry descends on San Francisco for JPM. Dealmakers, investors, and corporate leaders will gather to chart the course for 2025 and take stock of the landscape, both financial and political.
Endpoints News – Biotech and pharma business news, with a focus …
Catalyst Pharmaceuticals' controversial $375,000 rare autoimmune disease drug now won't face generic competition from Teva until Feb. 25, 2035, thanks to a ...
Xaira hires former Roche exec as CMO; ‘Tis the season for …
Dec 13, 2024 · The billion-dollar AI-focused startup Xaira Therapeutics deepened its C-suite this week, hiring former Roche executive Paulo Fontoura as its chief medical …
Exclusive: Two Vida Ventures co-founders exit the VC firm
Dec 10, 2024 · Arjun Goyal and Stefan Vitorovic, two of Vida Ventures' three co-founding managing directors, have exited the firm as it rejigs its leadership team seven years after launching.
Belharra Therapeutics sticks with lead programs, trims workforce …
Dec 9, 2024 · San Diego startup Belharra Therapeutics, a biotech creating small molecule cancer and immunology medicines, has laid off 21 employees, Endpoints News has confirmed. Belharra, from the same team as ...
Profluent debuts AI model for CRISPR gene editing design
Jan 7, 2025 · Profluent unveils Protein2PAM AI model to design CRISPR systems targeting more of human genome, CEO Ali Madani announces. Tool predicts PAM sequences for expanded gene editing.
FDA drug approvals 2024: Rare diseases, schizophrenia and …
Jan 6, 2025 · 2024’s novel drug approvals offered a wide array of new cancer drugs, rare disease treatments, a potential Alzheimer’s blockbuster, and about 10 fewer approvals than 2023. While 2022 and 2023 ...
Bayer exits Europe pact with Moberg for nail fungus drug after …
Dec 11, 2024 · Moberg Pharma's Terclara fails Phase 3 trial for fungal nail infection maintenance dosing; Bayer exits partnership and cancels European launch plans
Merus receives FDA accelerated approval to treat NRG1+ cancers
Dec 5, 2024 · The biotech Merus received the first-ever FDA accelerated approval for a systemic treatment targeting a specific genetic fusion in patients with either non-small cell lung cancer or pancreatic cancer.
Enanta's mid-stage win in pediatric RSV; Carisma to lay off 34% of …
Dec 9, 2024 · Enanta's oral N-protein inhibitor zelicapavir showed positive Phase 2 results in pediatric RSV. Carisma Therapeutics announces 34% workforce reduction. Innovent Biologics reports promising data ...